ストックスクリーナーアプリを入手
6.97
0.43%
0.03
プレマーケット:
6.81
-0.16
-2.30%
前日終値:
$6.94
開ける：
$6.96
24時間の取引高:
449.59K
Relative Volume:
0.80
時価総額：
$175.91M
収益：
$675.00K
当期純損益:
$-26.62M
株価収益率:
-4.4386
EPS:
-1.5703
ネットキャッシュフロー:
$-31.34M
1週間 パフォーマンス:
+8.06%
1か月 パフォーマンス:
+2.05%
6か月 パフォーマンス:
+45.21%
1年 パフォーマンス:
+1,074%
1日の値動き範囲:
$6.885
$7.25
1週間の範囲:
$6.40
$7.25
52週間の値動き範囲:
$0.47
$8.2457
Unicycive Therapeutics Inc Stock (UNCY) Company Profile
名前
Unicycive Therapeutics Inc
セクター
電話
650-384-0642
住所
4300 EL CAMINO REAL, SUITE 210, LOS ALTOS
Compare UNCY vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
UNCY
Unicycive Therapeutics Inc
|
6.97 | 175.91M | 675.00K | -26.62M | -31.34M | -1.5703 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 112.35B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.71B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 52.29B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 44.48B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 35.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Unicycive Therapeutics Inc Stock (UNCY) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-21 | 開始されました | Guggenheim | Buy |
| 2024-04-04 | 開始されました | Piper Sandler | Overweight |
Unicycive Therapeutics Inc (UNCY) 最新ニュース
UNCY Options Volatility — NASDAQ:UNCY - TradingView — Track All Markets
UNCY Options Chain — NASDAQ:UNCY - TradingView — Track All Markets
Equities Analysts Offer Predictions for UNCY Q1 Earnings - National Today
Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Kuehn Law Encourages Investors of Unicycive Therapeutics, Inc. t - GuruFocus
Unicycive Therapeutics to Present at Annual Healthcare Conference - National Today
Unicycive CEO to Present at Needham Conference - National Today
Kuehn Law Encourages Investors of Unicycive Therapeutics, Inc. to Contact Law Firm - PR Newswire
Unicycive Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference - The Manila Times
Brookline Capital Markets Estimates UNCY Q2 Earnings - MarketBeat
Market Leaders: Should you avoid Unicycive Therapeutics Inc stock right now2026 Big Picture & Verified Trade Idea Suggestions - baoquankhu1.vn
Growth Recap: What is the earnings history of Unicycive Therapeutics IncTreasury Yields & Real-Time Market Sentiment Reports - baoquankhu1.vn
Brookline Capital cuts Unicycive stock price target on share count By Investing.com - Investing.com Canada
Bronstein, Gewirtz & Grossman, LLC Encourages Unicycive Therapeutics, Inc. (UNCY) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
UNCY Stock Price, Quote & Chart | UNICYCIVE THERAPEUTICS INC (NASDAQ:UNCY) - ChartMill
Benchmark cuts Unicycive Therapeutics price target on updated assumptions By Investing.com - Investing.com Canada
Unicycive Therapeutics director Gaurav Aggarwal resigns from board - Investing.com UK
Unicycive Therapeutics director Gaurav Aggarwal resigns from board By Investing.com - Investing.com India
Unicycive Therapeutics, Inc. Files Form 8-K Announcing Departure and Appointment of Directors and Officers - Minichart
Unicycive Therapeutics (UNCY) director Gaurav Aggarwal steps down from board - Stock Titan
Unicycive Therapeutics | 8-K: Current report - Moomoo
Gaurav Aggarwal resigns from Unicycive Board - TradingView — Track All Markets
Unicycive Therapeutics, Inc. Announces Resignation of Gaurav Aggarwal from the Board of Directors, Effective April 6, 2026 - marketscreener.com
Benchmark Cuts Unicycive Therapeutics (NASDAQ:UNCY) Price Target to $15.00 - MarketBeat
Aug Movers: Should you avoid Unicycive Therapeutics Inc stock right now2026 Sentiment & Risk Managed Investment Entry Signals - baoquankhu1.vn
HC Wainwright Boosts Earnings Outlook for Unicycive Therapeutics - National Today
HC Wainwright Issues Positive Estimate for UNCY Earnings - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Unicycive Therapeutics, Inc. (UNCY) And Encourages Shareholders to Reach Out - ACCESS Newswire
Guggenheim Maintains Unicycive Therapeutics(UNCY.US) With Buy Rating, Cuts Target Price to $40 - Moomoo
Unicycive Therapeutics (UNCY) Target Price Lowered by Guggenheim | UNCY Stock News - GuruFocus
Guggenheim Has Lowered Expectations for Unicycive Therapeutics (NASDAQ:UNCY) Stock Price - MarketBeat
Noble Financial Has Positive Forecast for UNCY Q1 Earnings - MarketBeat
UNCY Retail Buzz Explodes 150% This Week as Traders Bet Big on Experimental Drug Approval - stocktwits.com
UNCY SEC FilingsUnicycive Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
H.C. Wainwright Sticks to Their Buy Rating for Unicycive Therapeutics (UNCY) - The Globe and Mail
Noble Financial Brokers Boost Earnings Estimates for UNCY - MarketBeat
H.C. Wainwright reiterates Unicycive stock rating, $22 target By Investing.com - Investing.com Canada
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Unicycive Therapeutics, Inc. (UNCY) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Noble Financial Maintains Unicycive Therapeutics(UNCY.US) With Buy Rating, Maintains Target Price $60 - Moomoo
Unicycive Therapeutics | 10-K: FY2025 Annual Report - Moomoo
Unicycive Therapeutics, Inc. (UNCY) Reports FY2025 Earnings - AlphaStreet
USA Rare Earth, Inc. (USAR) Reports Q4 Earnings - AlphaStreet
Unicycive Therapeutics Reports 2025 Financial Results; OLC NDA Under FDA Review with Potential Approval in June 2026 - Minichart
Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update - National Today
Unicycive Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Unicycive Therapeutics (NASDAQ:UNCY) Releases Quarterly Earnings Results, Misses Estimates By $0.36 EPS - MarketBeat
Unicycive (UNCY) narrows 2025 loss, FDA accepts kidney drug NDA resubmission - Stock Titan
Unicycive Therapeutics : March 2026 Corporate Presentation - marketscreener.com
Unicycive Therapeutics 10-K: Net loss $26.6M, EPS $(1.67) - TradingView
Unicycive (NASDAQ: UNCY) advances OLC NDA toward June 2026 PDUFA as UNI-494 is paused - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Encourages Unicycive Therapeutics, Inc. (UNCY) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Unicycive Therapeutics Inc (UNCY) 財務データ
収益
当期純利益
現金流量
EPS
2.69%
0.25%
大文字化:
|
ボリューム (24 時間):